The ENERGY 3 Study: A Randomized, Controlled, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Children with Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency
Primary Objective
A Randomized, Controlled, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Children with Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency
Description
A Randomized, Controlled, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Children with Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency
Details
Age
Child
Eligibility
Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency
Locations
Childrens Hospital Colorado
Principal Investigator
Nina Ma
Study ID
Protocol Number: 23-1932
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers